Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Neurobiol Dis ; 50: 42-8, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23017648

RESUMEN

Lewy pathology affects the gastrointestinal tract in Parkinson's disease (PD) and data from recent genetic studies suggest a link between PD and gut inflammation. We therefore undertook the present survey to investigate whether gastrointestinal inflammation occurs in PD patients. Nineteen PD patients and 14 age-matched healthy controls were included. For each PD patients, neurological and gastrointestinal symptoms were assessed using the Unified Parkinson's Disease Rating Scale part III and the Rome III questionnaire, respectively and cumulative lifetime dose of L-dopa was calculated. Four biopsies were taken from the ascending colon during the course of a total colonoscopy in controls and PD patients. The mRNA expression levels of pro-inflammatory cytokines (tumor necrosis factor alpha, interferon gamma, interleukin-6 and interleukin-1 beta) and glial marker (Glial fibrillary acidic protein, Sox-10 and S100-beta) were analyzed using real-time PCR in two-pooled biopsies. Immunohistochemical analysis was performed on the two remaining biopsies using antibodies against phosphorylated alpha-synuclein to detect Lewy pathology. The mRNA expression levels of pro-inflammatory cytokines as well as of two glial markers (Glial fibrillary acidic protein and Sox-10) were significantly elevated in the ascending colon of PD patients with respect to controls. The levels of tumor necrosis factor alpha, interferon gamma, interleukin-6, interleukin-1 beta and Sox-10 were negatively correlated with disease duration. By contrast, no correlations were found between the levels of pro-inflammatory cytokines or glial markers and disease severity, gastrointestinal symptoms or cumulative lifetime dose of L-dopa. There was no significant difference in the expression of pro-inflammatory cytokines or glial marker between patients with and without enteric Lewy pathology. Our findings provide evidence that enteric inflammation occurs in PD and further reinforce the role of peripheral inflammation in the initiation and/or the progression of the disease.


Asunto(s)
Colitis/etiología , Inflamación/etiología , Cuerpos de Lewy/patología , Enfermedad de Parkinson/complicaciones , Adulto , Anciano , Colitis/inmunología , Colitis/patología , Citocinas/biosíntesis , Femenino , Humanos , Inflamación/inmunología , Inflamación/patología , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/inmunología , Enfermedad de Parkinson/patología , ARN Mensajero/análisis , Reacción en Cadena en Tiempo Real de la Polimerasa
2.
J Physiol ; 590(11): 2739-50, 2012 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-22473776

RESUMEN

Increasing evidence suggests that enteric glial cells (EGCs) are critical for enteric neuron survival and functions. In particular, EGCs exert direct neuroprotective effects mediated in part by the release of glutathione. However, other glial factors such as those identified as regulating the intestinal epithelial barrier and in particular the omega-6 fatty acid derivative 15-deoxy-Δ¹²,¹4-prostaglandin J2 (15d-PGJ2) could also be involved in EGC-mediated neuroprotection. Therefore, our study aimed to assess the putative role of EGC-derived 15d-PGJ2 in their neuroprotective effects. We first showed that pretreatment of primary cultures of enteric nervous system(ENS)or humann euroblastoma cells (SH-SY5Y)with 15d-PGJ2 dose dependently prevented hydrogen peroxide neurotoxicity. Furthermore, neuroprotective effects of EGCs were significantly inhibited following genetic invalidation in EGCs of the key enzyme involved in 15d-PGJ2 synthesis, i.e. L-PGDS. We next showed that 15d-PGJ2 effects were mediated by an Nrf2 dependent pathway but were not blocked by PPARγ inhibitor (GW9662) in SH-SY5Y cells and enteric neurons. Finally, 15d-PGJ2 induced a significant increase in glutamate cysteine ligase expression and intracellular glutathione in SH cells and enteric neurons. In conclusion, we identified 15d-PGJ2 as a novel glial-derived molecule with neuroprotective effects in the ENS. This study further supports the concept that omega-6 derivatives such as 15d-PGJ2 might be used in preventive and/or therapeutic strategies for the treatment of enteric neuropathies.


Asunto(s)
Plexo Mientérico/metabolismo , Neuroglía/metabolismo , Prostaglandina D2/análogos & derivados , Animales , Línea Celular , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Glutatión/metabolismo , Humanos , Peróxido de Hidrógeno/farmacología , Oxidorreductasas Intramoleculares/fisiología , Lipocalinas/fisiología , Factor 2 Relacionado con NF-E2/metabolismo , Estrés Oxidativo , Fosfopiruvato Hidratasa/metabolismo , Prostaglandina D2/metabolismo , Ratas
3.
Am J Physiol Gastrointest Liver Physiol ; 303(8): G887-93, 2012 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-22878122

RESUMEN

The enteric nervous system (ENS), a major regulatory system for gastrointestinal function, is composed of neurons and enteric glial cells (EGCs). Enteric glia have long been thought to provide only structural support to neurons. However, recent evidence indicates enteric glia-neuron cross talk significantly contributes to neuronal maintenance, survival, and function. Thus damage to EGCs may trigger neurodegenerative processes thought to play a role in gastrointestinal dysfunctions and symptoms. The purpose of this review is to provide an update on EGCs, particularly focusing on their possible neuroprotective features and the resultant enteric neuron abnormalities subsequent to EGC damage. These neuroprotective mechanisms may have pathogenetic relevance in a variety of functional and inflammatory gut diseases. Basic and clinical (translational) studies support a neuroprotective role mediated by EGCs. Different models have been developed to test whether selective EGC damage/ablation has an impact on gut functions and the ENS. Preclinical data indicated that selective EGC alterations were associated with changes in gut physiology related to enteric neuron abnormalities. In humans, a substantial loss of EGCs was described in patients with various functional and/or inflammatory gastrointestinal diseases. However, whether EGC changes precede or follow neuronal degeneration and loss and how this damage occurs is not defined. Additional studies on EGC neuroprotective capacity are expected to improve knowledge of gut diseases and pave the way for targeted therapeutic strategies of underlying neuropathies.


Asunto(s)
Comunicación Celular/fisiología , Citoprotección/fisiología , Sistema Nervioso Entérico/fisiología , Neuroglía/fisiología , Neuronas/fisiología , Animales , Humanos
4.
FASEB J ; 24(4): 1082-94, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19906678

RESUMEN

Enteric glial cells (EGCs) are essential in the control of gastrointestinal functions. Although lesions of EGCs are associated with neuronal degeneration in animal models, their direct neuroprotective role remains unknown. Therefore, the aims of this study were to demonstrate the direct neuroprotective effects of EGCs and to identify putative glial mediators involved. First, viral targeted ablation of EGCs in primary cultures of enteric nervous system increased neuronal death both under basal conditions and in the presence of oxidative stress (dopamine, hydrogen peroxide). Second, direct or indirect coculture experiments of EGC lines with primary cultures of enteric nervous system or neuroblastoma cell lines (SH-SY5Y) prevented neurotoxic effects induced by oxidative stress (increased membrane permeability, release of neuronal specific enolase, caspase-3 immunoreactivity, changes in [Ca(2+)](i) response). Finally, combining pharmacological inhibition and mRNA silencing methods, we demonstrated that neuroprotective effects of EGCs were mediated in part by reduced glutathione but not by oxidized glutathione or by S-nitrosoglutathione. Our study identified the neuroprotective effects of EGCs via their release of reduced glutathione, extending their critical role in physiological contexts and in enteric neuropathies.-Abdo, H., Derkinderen, P., Gomes, P., Chevalier, J., Aubert, P., Masson, D., Galmiche, J.-P., Vanden Berghe, P., Neunlist, M., Lardeux, B. Enteric glial cells protect neurons from oxidative stress in part via reduced glutathione.


Asunto(s)
Tracto Gastrointestinal/metabolismo , Glutatión/metabolismo , Neuronas/metabolismo , Estrés Oxidativo , Animales , Calcio/metabolismo , Caspasa 3/genética , Caspasa 3/metabolismo , Línea Celular Tumoral , Dopamina/farmacología , Femenino , Tracto Gastrointestinal/inervación , Silenciador del Gen/efectos de los fármacos , Peróxido de Hidrógeno/farmacología , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/metabolismo , Neuroglía , Oxidantes/farmacología , Oxidación-Reducción/efectos de los fármacos , Fosfopiruvato Hidratasa/genética , Fosfopiruvato Hidratasa/metabolismo , Embarazo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley
5.
J Physiol ; 588(Pt 14): 2533-44, 2010 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-20478974

RESUMEN

The enteric nervous system (ENS) and its major component, enteric glial cells (EGCs), have recently been identified as a major regulator of intestinal epithelial barrier functions. Indeed, EGCs inhibit intestinal epithelial cell (IEC) proliferation and increase barrier resistance and IEC adhesion via the release of EGC-derived soluble factors. Interestingly, EGC regulation of intestinal epithelial barrier functions is reminiscent of previously reported peroxisome proliferator-activated receptor gamma (PPARgamma)-dependent functional effects. In this context, the present study aimed at identifying whether EGC could synthesize and release the main PPARgamma ligand, 15-deoxy-(12,14)-prostaglandin J2 (15dPGJ2), and regulate IEC functions such as proliferation and differentiation via a PPARgamma dependent pathway. First, we demonstrated that the lipocalin but not the haematopoetic form for prostaglandin D synthase (PGDS), the enzyme responsible of 15dPGJ2 synthesis, was expressed in EGCs of the human submucosal plexus and of the subepithelium, as well as in rat primary culture of ENS and EGC lines. Next, 15dPGJ2 was identified in EGC supernatants of various EGC lines. 15dPGJ2 reproduced EGC inhibitory effects upon IEC proliferation, and inhibition of lipocalin PGDS expression by shRNA abrogated these effects. Furthermore, EGCs induced nuclear translocation of PPARgamma in IEC, and both EGC and 15dPGJ2 effects upon IEC proliferation were prevented by the PPARgamma antagonist GW9662. Finally, EGC induced differentiation-related gene expression in IEC through a PPARgamma-dependent pathway. Our results identified 15dPGJ2 as a novel glial-derived mediator involved in the control of IEC proliferation/differentiation through activation of PPARgamma. They also suggest that alterations of glial PGDS expression may modify intestinal epithelial barrier functions and be involved in the development of pathologies such as cancer or inflammatory bowel diseases.


Asunto(s)
Diferenciación Celular/fisiología , Proliferación Celular , Sistema Nervioso Entérico/fisiología , Mucosa Intestinal/fisiología , Neuroglía/fisiología , Prostaglandina D2/análogos & derivados , Animales , Células Cultivadas , Humanos , Mucosa Intestinal/inervación , Oxidorreductasas Intramoleculares/análisis , Oxidorreductasas Intramoleculares/metabolismo , Oxidorreductasas Intramoleculares/fisiología , Lipocalinas/análisis , Lipocalinas/metabolismo , Lipocalinas/fisiología , PPAR gamma/análisis , PPAR gamma/antagonistas & inhibidores , PPAR gamma/metabolismo , PPAR gamma/fisiología , Prostaglandina D2/biosíntesis , Prostaglandina D2/metabolismo , Prostaglandina D2/fisiología , Ratas , Ratas Sprague-Dawley
6.
Biochim Biophys Acta ; 1783(2): 188-92, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18070606

RESUMEN

Aberrant phosphorylation of tau protein on serine and threonine residues has been shown to be critical in neurodegenerative disorders called tauopathies. An increasing amount of data suggest that tyrosine phosphorylation of tau might play an equally important role in pathology, with at least three putative tyrosine kinases of tau identified to date. It was recently shown that the tyrosine kinase Syk could efficiently phosphorylate alpha-synuclein, the aggregated protein found in Parkinson's disease and other synucleinopathies. We report herein that Syk is also a tau kinase, phosphorylating tau in vitro and in CHO cells when both proteins are expressed exogenously. In CHO cells, we have also demonstrated by co-immunoprecipitation that Syk binds to tau. Finally, by site-directed mutagenesis substituting the tyrosine residues of tau with phenylalanine, we established that tyrosine 18 was the primary residue in tau phosphorylated by Syk. The identification of Syk as a common tyrosine kinase of both tau and alpha-synuclein may be of potential significance in neurodegenerative disorders and also in neuronal physiology. These results bring another clue to the intriguing overlaps between tauopathies and synucleinopathies and provide new insights into the role of Syk in neuronal physiology.


Asunto(s)
Péptidos y Proteínas de Señalización Intracelular/metabolismo , Proteínas Tirosina Quinasas/metabolismo , Proteínas tau/metabolismo , Animales , Células CHO , Cricetinae , Cricetulus , Humanos , Fosfatos/metabolismo , Fosforilación , Fosfotirosina/metabolismo , Especificidad por Sustrato , Quinasa Syk , Factores de Tiempo
7.
Biochem Biophys Res Commun ; 382(3): 577-82, 2009 May 08.
Artículo en Inglés | MEDLINE | ID: mdl-19302981

RESUMEN

Neurons of enteric nervous system (ENS) regulate intestinal epithelial cells (IEC) functions but whether IEC can impact upon the neurochemical coding and survival of enteric neurons remain unknown. Neuro-epithelial interactions were studied using a coculture model composed of IEC lines and primary culture of rat ENS or human neuroblastoma cells (SH-SY5Y). Neurochemical coding of enteric neurons was analysed by immunohistochemistry and quantitative PCR. Neuroprotective effects of IEC were tested by measuring neuron specific enolase (NSE) release or cell permeability to 7-amino-actinomycin D (7-AAD). Following coculture with IEC, the percentage of VIP-immunoreactive (IR) neurons but not NOS-IR and VIP mRNA expression were significantly increased. IEC significantly reduced dopamine-induced NSE release and 7-AAD permeability in culture of ENS and SH-SY5Y, respectively. Finally, we showed that NGF had neuroprotective effects but reduced VIP expression in enteric neurons. In conclusion, our study identified a novel role for IEC in the regulation of enteric neuronal properties.


Asunto(s)
Mucosa Intestinal/fisiología , Intestinos/inervación , Plasticidad Neuronal , Neuronas/fisiología , Animales , Dactinomicina/análogos & derivados , Dactinomicina/metabolismo , Colorantes Fluorescentes/metabolismo , Humanos , Intestinos/citología , Intestinos/fisiología , Neuronas/enzimología , Fosfopiruvato Hidratasa/metabolismo , Ratas
8.
Cancer Res ; 62(17): 4977-84, 2002 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-12208749

RESUMEN

Vascular endothelial growth factor (VEGF) is a potent angiogenic and prognostic factor for many tumors, including those of endocrine-responsive tissues such as the breast and uterus. Recent studies indicate that 17beta-estradiol (E(2)) modulates VEGF expression in breast and uterine cells, involving transcriptional activation through estrogen receptor (ER) alpha. However, molecular mechanisms of VEGF regulation mediated by the two ER subtypes and the potential role of ERbeta in the control of breast cancer angiogenesis have not yet been investigated. In transient transfection assays using the VEGF(-2275/+54) promoter-luciferase construct, E(2) (1 nM) increased transcription activity in MCF-7 cells (either untransfected or cotransfected with ERalpha) and it increased transcription activity in MDA-MB-231 cells cotransfected with ERalpha or ERbeta (1.8- and 2-fold induction, respectively). The positive effect was abolished when MCF-7 cells were treated with pure antiestrogen ICI 182,780 or the agonist/antagonist tamoxifen (1 micro M). To identify response elements involved in this transcriptional regulation, MCF-7 or MDA-MB-231 cells were transfected with several deletion constructs of the VEGF promoter. Deletion of 1.2-2.3 kb upstream to the transcription start in the VEGF promoter abrogated E(2)-dependent transcription in these cells. This region contains an imperfect estrogen-responsive element (ERE), ERE1520, and one activator protein 1 site. Transfection of MCF-7 cells (ERalpha) with the ERE1520-luciferase construct conferred transcriptional activity with 1 nM E(2) (1.9-fold induction). Also, the imperfect ERE formed a complex with ERalpha or ERbeta proteins in gel shift assay using MCF-7 or MDA-MB-231 nuclear extracts. In contrast to ERalpha, ERbeta could transactivate VEGF reporter construct in MDA-MB-231 cells, in the presence of E(2) or tamoxifen, suggesting different transactivational mechanisms between ERalpha and ERbeta in the presence of tamoxifen. Interestingly, E(2) inhibited VEGF transcription in MCF-7 cells transfected with ERbeta or MDA-MB-231 cells cotransfected with ERalpha and ERbeta, suggesting that heterodimerization of ERalpha/ERbeta has the ability to inhibit E(2)-induced VEGF expression in breast cancer cells. These results demonstrate that VEGF is a target gene for ERalpha and ERbeta in breast cancer cells; it remains to be determined whether ERalpha and ERbeta expression in breast biopsies correlates with VEGF expression and vascular density.


Asunto(s)
Neoplasias de la Mama/metabolismo , Factores de Crecimiento Endotelial/biosíntesis , Estradiol/farmacología , Linfocinas/biosíntesis , Receptores de Estrógenos/fisiología , Tamoxifeno/farmacología , Neoplasias de la Mama/genética , Factores de Crecimiento Endotelial/genética , Receptor alfa de Estrógeno , Receptor beta de Estrógeno , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Linfocinas/genética , Regiones Promotoras Genéticas , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Elementos de Respuesta/genética , Transcripción Genética/efectos de los fármacos , Transcripción Genética/fisiología , Células Tumorales Cultivadas , Regulación hacia Arriba/efectos de los fármacos , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial Vascular
9.
Anticancer Res ; 25(1A): 243-8, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15816544

RESUMEN

BACKGROUND: Inherited mutations of the BRCA1 gene are responsible for hereditary breast and ovarian cancer syndrome. However, little is known of how disruption of BRCA1 functions preferentially increases cancer risk in hormone-dependent organs. We aimed to study whether BRCA1 was regulated by progesterone in the MCF7 breast cancer cell line. MATERIALS AND METHODS: MCF7 breast cancer cells were incubated with 10(-4) or 10(-10) M progesterone for 24 or 48 hours. BRCA1 expression, proliferation and apoptosis were analysed. RESULTS: 10(-4) M progesterone decreased cell proliferation, cell cycle progression and induced apoptosis. In addition, BRCA1 and cyclin A mRNA decreased. In contrast, none of these effects were observed in MCF7 cells incubated with 10(-10) M progesterone. CONCLUSION: The down-regulation of BRCA1 in MCF7 cells incubated with 10(-4) M progesterone seems to be a consequence of cell cycle alterations rather than a direct effect of the hormone on BRCA1.


Asunto(s)
Proteína BRCA1/genética , Neoplasias de la Mama/genética , Progesterona/farmacología , Apoptosis/efectos de los fármacos , Proteína BRCA1/biosíntesis , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Ciclinas/biosíntesis , Ciclinas/genética , Humanos , ARN Mensajero/genética , ARN Mensajero/metabolismo , Receptores de Estrógenos/biosíntesis , Receptores de Progesterona/biosíntesis
10.
Nutrition ; 21(6): 732-9, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15925299

RESUMEN

OBJECTIVE: Ornithine alpha-ketoglutarate (OKG) displays anabolic properties at the hepatic level, but the mechanisms involved remain unclear. This study investigated in vivo the ability of OKG to modulate hepatic gene expression of three liver-secreted proteins: albumin, transthyretin, and retinol binding protein. METHODS: One hundred eighty rats were fed for 5 d with a balanced regimen enriched with OKG (5 g.kg(-1).d(-1)) or an isonitrogenous mixture (alanine, glycine, and serine). Hepatic mRNA levels and plasma concentrations of the three proteins studied were determined at the end of the nutrition period and after 1, 2, and 3 d of food deprivation. Results were compared by analysis of variance and Bonferroni-Dunn tests. RESULTS: At the end of the nutrition period, hepatic mRNA levels and plasma concentrations of the three proteins were not modified by OKG supplementation. However, OKG largely increased mRNA levels of albumin, transthyretin, and retinol binding protein on the first day of starvation compared with control animals (+68%, +64% and +51%, respectively; P < 0.01 versus control). OKG precociously increased albuminemia (on day 2) but had no effect on plasma concentrations of transthyretin and retinol binding protein. Neither regulation of polyamine hepatic concentration nor alteration in hepatic amino acid content seemed to be implicated in these actions. CONCLUSION: This study is the first to demonstrate that OKG regulates in vivo liver gene expression during acute malnutrition by modulating hepatic mRNA levels.


Asunto(s)
Hígado/metabolismo , Ornitina/análogos & derivados , Biosíntesis de Proteínas/efectos de los fármacos , ARN Mensajero/metabolismo , Inanición/metabolismo , Albúminas/genética , Albúminas/metabolismo , Análisis de Varianza , Animales , Modelos Animales de Enfermedad , Hígado/efectos de los fármacos , Masculino , Ornitina/farmacología , Prealbúmina/genética , Prealbúmina/metabolismo , Distribución Aleatoria , Ratas , Ratas Wistar , Proteínas de Unión al Retinol/genética , Proteínas de Unión al Retinol/metabolismo , Proteínas Plasmáticas de Unión al Retinol
11.
Thromb Haemost ; 91(3): 569-75, 2004 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-14983234

RESUMEN

Tissue factor pathway inhibitor-2 (TFPI-2) is a recently described serine proteinase inhibitor. Human and murine TFPI-2 share about 50% homology. The aim of this study was to investigate the cellular localization of human and murine TFPI-2 in the liver and the regulation of their expression during acute inflammation. Northern blot, in situ hybridization and studies on isolated hepatocytes demonstrated a high-level expression of TFPI-2 in murine hepatocytes. On the other hand, very little TFPI-2 mRNA expression could be detected in human liver. Studies with isolated human liver cells suggested that TFPI-2 expression in human liver was mainly observed in liver sinusoidal endothelial cells rather than hepatocytes. Liver murine TFPI-2 expression was greatly increased after lipopolysaccharide administration with a delayed kinetics as compared to alpha1-acid glycoprotein, a classical acute-phase reactant. Accordingly, studies with isolated cells showed that the increase in TFPI-2 transcripts occurred in non-hepatocytic cells. Moreover, the LPS response was abolished in mice with a hepatocyte-specific KO for the gp130 receptor, thus indicating that a mediator from hepatocytes is involved in the up-regulation of TFPI-2 in non-parenchymal cells. In conclusion, murine TFPI-2 is highly expressed in hepatocytes in the normal murine liver and is upregulated in non-parenchymal cells in the context of inflammation. The large difference in the level of liver expression of human and murine TFPI-2 suggests that despite significant sequence similarities, these proteins presumably have different functions in the two species.


Asunto(s)
Glicoproteínas/biosíntesis , Inflamación/metabolismo , Hígado/metabolismo , Reacción de Fase Aguda , Animales , Antígenos CD/metabolismo , Northern Blotting , Receptor gp130 de Citocinas , Endopeptidasas/metabolismo , Hepatocitos/metabolismo , Humanos , Hibridación in Situ , Interleucina-6/metabolismo , Cinética , Lipopolisacáridos/metabolismo , Glicoproteínas de Membrana/metabolismo , Ratones , Ratones Endogámicos BALB C , Ratones Noqueados , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Especificidad de la Especie , Factores de Tiempo , Regulación hacia Arriba
12.
J Biol Chem ; 281(10): 6211-8, 2006 Mar 10.
Artículo en Inglés | MEDLINE | ID: mdl-16407292

RESUMEN

Familial autosomal dominant hypercholesterolemia is associated with high risk for cardiovascular accidents and is related to mutations in the low density lipoprotein receptor or its ligand apolipoprotein B (apoB). Mutations in a third gene, proprotein convertase subtilisin kexin 9 (PCSK9), were recently associated to this disease. PCSK9 acts as a natural inhibitor of the low density lipoprotein receptor pathway, and both genes are regulated by depletion of cholesterol cell content and statins, via sterol regulatory element-binding protein (SREBP). Here we investigated the regulation of PCSK9 gene expression during nutritional changes. We showed that PCSK9 mRNA quantity is decreased by 73% in mice after 24 h of fasting, leading to a 2-fold decrease in protein level. In contrast PCSK9 expression was restored upon high carbohydrate refeeding. PCSK9 mRNA increased by 4-5-fold in presence of insulin in rodent primary hepatocytes, whereas glucose had no effect. Moreover, insulin up-regulated hepatic PCSK9 expression in vivo during a hyperinsulinemic-euglycemic clamp in mice. Adenoviral mediated overexpression of a dominant or negative form of SREBP-1c confirmed the implication of this transcription factor in insulin-mediated stimulation of PCSK9 expression. Liver X receptor agonist T0901317 also regulated PCSK9 expression via this same pathway (a 2-fold increase in PCSK9 mRNA of primary hepatocytes cultured for 24 h in presence of 1 microm T0901317). As our last investigation, we isolated PCSK9 proximal promoter and verified the functionality of a SREBP-1c responsive element located from 335 bp to 355 bp upstream of the ATG. Together, these results show that PCSK9 expression is regulated by nutritional status and insulinemia.


Asunto(s)
Hepatocitos/enzimología , Insulina/fisiología , Fenómenos Fisiológicos de la Nutrición/fisiología , Serina Endopeptidasas/biosíntesis , Serina Endopeptidasas/genética , Proteína 1 de Unión a los Elementos Reguladores de Esteroles/fisiología , Animales , Secuencia de Bases , Células Cultivadas , Proteínas de Unión al ADN/agonistas , Ayuno/metabolismo , Femenino , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Humanos , Hidrocarburos Fluorados , Receptores X del Hígado , Masculino , Ratones , Ratones Endogámicos C57BL , Datos de Secuencia Molecular , Receptores Nucleares Huérfanos , Regiones Promotoras Genéticas , Proproteína Convertasa 9 , Proproteína Convertasas , ARN Mensajero/metabolismo , Ratas , Receptores Citoplasmáticos y Nucleares/agonistas , Elementos Reguladores de la Transcripción/fisiología , Sulfonamidas/farmacología
13.
J Hepatol ; 36(3): 385-94, 2002 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11867183

RESUMEN

BACKGROUND/AIMS: Fas-induced apoptosis is one of the main forms of apoptosis occurring in hepatocytes. We have previously demonstrated that the human hepatoma cell line Hep3B is resistant to Fas-mediated apoptosis. In this study, we investigated whether the human Fas receptor itself, or the Fas transduction pathway was responsible for the resistant phenotype. METHODS: Clones of Hep3B cells overexpressing the mouse Fas gene (Hep3B(mfas)) were generated by transfection, and apoptosis was studied by (i) chromatin condensation and nuclear fragmentation, (ii) flow cytometry, (iii) DNA fragmentation and (iv) poly (ADP-ribose) polymerase cleavage. RESULTS: Use of the species-specific and agonistic anti-mFas monoclonal antibody (JO2), showed that the mFas receptor was correctly routed to the plasma membrane of Hep3B(mfas) cells. Using the four above-mentioned criteria, we demonstrated that JO2 triggered mFas-mediated apoptosis of Hep3B(mfas), but not of Hep3B(pCi) cells (transfected with an empty vector). CONCLUSIONS: Our data show (i) that the Fas signaling pathway can be completed when a functional mFas receptor is expressed in Hep3B cells, and thus, (ii) that the death-inducing signaling complex components and the effector caspases are functional in Hep3B cells. Moreover, they suggest that the Fas subunits are not pre-assembled at the cell membrane before receptor-ligand interaction.


Asunto(s)
Carcinoma Hepatocelular , Fragmentación del ADN/fisiología , Neoplasias Hepáticas , Receptor fas/genética , Receptor fas/metabolismo , Caspasa 3 , Caspasa 8 , Caspasa 9 , Caspasas/genética , Membrana Celular/metabolismo , Cromatina/metabolismo , Coenzima A Ligasas/genética , Proteínas de Escherichia coli/genética , Regulación Neoplásica de la Expresión Génica , Humanos , Fenotipo , Mutación Puntual , Poli(ADP-Ribosa) Polimerasa-1 , Poli(ADP-Ribosa) Polimerasas , Proteínas/metabolismo , Transfección , Células Tumorales Cultivadas/citología , Células Tumorales Cultivadas/fisiología
14.
J Hepatol ; 37(1): 63-71, 2002 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12076863

RESUMEN

BACKGROUND/AIMS: Hepatitis B and C viruses, two inducers of hepatocarcinomas, have been shown to activate AP-1, NF-kappa B and STAT in vitro, but no detailed information on the activity of these transcription factors in vivo have been provided. METHODS: We have measured the DNA binding activity of these transcription factors in the peri-tumoral and the tumoral parts of 15 primary liver cancers, of viral or non-viral etiologies, and in five hepatic metastases using electrophoretic mobility shift assays. RESULTS: AP-1, NF-kappa B and STAT binding activities were increased in the peritumoral tissue, compared with histologically normal livers in 73, 87 and 70%, respectively, of the cases. A further activation of AP-1, NF-kappa B, but not STAT binding in the tumoral parts was detected in 40 and 80%, respectively, of the cases. A close correlation was found between JunD and c-Jun levels and AP-1 binding activity at the tumoral stage. By contrast, AP-1 and NF-kappa B binding activities were low or only slightly elevated in the peri-tumoral and the tumoral tissue of metastases. CONCLUSIONS: Early activation of AP-1, NF-kappa B and STAT contributes probably to the acquisition of a transformed phenotype during hepatocarcinogenesis, whatever the etiology.


Asunto(s)
Carcinoma Hepatocelular/fisiopatología , Proteínas de Unión al ADN/metabolismo , Neoplasias Hepáticas/fisiopatología , FN-kappa B/metabolismo , Transactivadores/metabolismo , Factor de Transcripción AP-1/metabolismo , Regulación Neoplásica de la Expresión Génica , Humanos , Antígeno Nuclear de Célula en Proliferación/genética , Proteínas Proto-Oncogénicas c-fos/genética , Proteínas Proto-Oncogénicas c-jun/genética , ARN Mensajero/análisis , Factor de Transcripción STAT1
15.
Hepatology ; 36(5): 1070-8, 2002 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-12395316

RESUMEN

In cirrhosis, lipopolysaccharide (LPS, a product of Gram-negative bacteria) in the blood may cause septic shock. LPS-elicited induction of arterial inducible nitric oxide synthase (iNOS) results in nitric oxide (NO)-induced vasodilation, which causes arterial hypotension and hyporeactivity to alpha(1)-adrenergic constrictors. In vitro studies have suggested that vasopressin inhibits iNOS expression in cultured vascular smooth muscle cells exposed to LPS. Thus, the aim of this study was to investigate the effects of terlipressin administration (a vasopressin analog) on in vivo LPS-induced aortic iNOS in rats with cirrhosis. LPS (1 mg/kg, intravenously) was administered followed by the intravenous administration of terlipressin (0.05 mg/kg, intravenously) or placebo 1 hour later. Arterial pressure was measured, and contractions to phenylephrine (an alpha(1)-adrenoceptor agonist), iNOS activity, and iNOS expressions (mRNA and protein) were investigated in isolated aortas. LPS-induced arterial hypotension and aortic hyporeactivity to phenylephrine were abolished in rats that received terlipressin. LPS-induced aortic iNOS activity and expression were suppressed in terlipressin-treated rats. In conclusion, in LPS-challenged rats with cirrhosis, terlipressin administration inhibits in vivo LPS-induced aortic iNOS expression. Terlipressin administration may be a novel approach for the treatment of arterial hypotension and hyporeactivity to alpha(1)-adrenergic constrictors in patients with cirrhosis and septic shock.


Asunto(s)
Cirrosis Hepática Biliar/metabolismo , Lipresina/análogos & derivados , Lipresina/farmacología , Lisina/análogos & derivados , Óxido Nítrico Sintasa/metabolismo , Choque Séptico/tratamiento farmacológico , Vasoconstrictores/farmacología , Alanina Transaminasa/sangre , Animales , Aorta Torácica/enzimología , Presión Sanguínea/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Hipotensión/inducido químicamente , Hipotensión/tratamiento farmacológico , Hipotensión/metabolismo , Lipopolisacáridos , Cirrosis Hepática Biliar/tratamiento farmacológico , Lisina/farmacología , Masculino , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa/genética , Óxido Nítrico Sintasa de Tipo II , Fenilefrina/farmacología , ARN Mensajero/análisis , Ratas , Ratas Sprague-Dawley , Choque Séptico/inducido químicamente , Choque Séptico/metabolismo , Terlipresina , Factor de Necrosis Tumoral alfa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA